A study led by Xue, Zhou and Chen reports that sequential PD‑1 inhibitor therapy given after CD19 CAR‑T cell treatment enhances outcomes in relapsed and refractory non-Hodgkin lymphoma. The research suggests PD‑1 blockade can act as consolidative therapy to deepen and sustain responses following CAR‑T, offering a potential post-CAR-T strategy in a patient population with high unmet need. Investigators emphasized the need for confirmatory trials to define optimal timing and safety in broader cohorts.